Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director · President and CEO | February 10, 2026 | February 12, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | December 22, 2025 | December 23, 2025 |
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP & President, International | February 22, 2021 | February 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date February 10, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 176,629 |
Reported balance
After 2026-02-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-10 · Grant · Acquired 79,264 · Balance 176,629 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. F2: Includes 376 shares acquired on July 18, 2025 under the Issuer's employee stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 209,160 |
Reported balance
After 2026-02-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-10 · Grant · Acquired 32,531 · Balance 209,160 F3: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,531 performance share units ("PSUs") granted in the Issuer's 2025 fiscal year. |
| Common StockSEC Table I · non-derivative | Direct | 197,864 |
Reported balance
After 2026-02-10 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-02-10 · Tax withholding · Disposed 11,296 · Balance 197,864 F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
F2: Includes 376 shares acquired on July 18, 2025 under the Issuer's employee stock purchase plan.
F3: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,531 performance share units ("PSUs") granted in the Issuer's 2025 fiscal year.
F4: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
Dyne Therapeutics, Inc.
Report date December 22, 2025 · Filed December 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.78 · Expires 2035-12-21 | Direct | 59,665 |
Reported balance
After 2025-12-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-22 · Grant · Acquired 59,665 · Balance 59,665 F1: The option was granted on December 22, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments through December 22, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on December 22, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments through December 22, 2028.
Horizon Therapeutics Public Ltd Co
Report date February 22, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 104,165 |
Ending reported balance
After 2021-02-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-22 · Sale · Disposed 7,713 · Balance 104,810 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2020. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.71 to $87.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2021-02-22 · Sale · Disposed 645 · Balance 104,165 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2020. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.14 to $88.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2020.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.71 to $87.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.14 to $88.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2026 Filed Feb 12, 2026 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 11,296 | $46.75 | $528,088.00 |
DisclosureSEC source: 0001699488-26-000002 · form4-02122026_040217.xml · nonDerivative · entry 3 Karnani Vikram · CIK 0001699488 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,864 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 32,531 | $0.00 | $0.00 |
DisclosureSEC source: 0001699488-26-000002 · form4-02122026_040217.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,160 F3 · shares: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 32,531 performance share units ("PSUs") granted in the Issuer's 2025 fiscal year. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 79,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001699488-26-000002 · form4-02122026_040217.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,629 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. F2 · balance_after: Includes 376 shares acquired on July 18, 2025 under the Issuer's employee stock purchase plan. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 21:08 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock option (right to buy) · Derivative | 59,665 | $0.00 Strike: $20.78 | $0.00 |
DisclosureSEC source: 0001193125-25-330863 · ownership.xml · derivative · entry 1 Karnani Vikram · CIK 0001699488 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,665 Underlying: Common Stock · 59,665 shares Expires 2035-12-21 F1 · derivative.exercise_date: The option was granted on December 22, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments through December 22, 2028. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:13 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 8,983 | $47.35 | $425,345.05 |
DisclosureSEC source: 0001699488-25-000004 · form4-11142025_091156.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,989 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:50 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 130,344 | $0.00 Strike: $31.41 | $0.00 |
DisclosureSEC source: 0001062993-24-019165 · form4.xml · derivative · entry 2 Karnani Vikram · CIK 0001699488 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,344 Underlying: Common Stock · 130,344 shares Expires 2034-11-12 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option shall vest and become exercisable on November 12, 2025, with the balance vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:50 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 105,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-019165 · form4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,972 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on November 12, 2025, with the balance vesting in three annual installments thereafter, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 18:20 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 645 | $88.45 | $57,050.38 |
DisclosureSEC source: 0001209191-21-013382 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,165 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.14 to $88.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 18:20 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 7,713 | $87.08 | $671,671.18 |
DisclosureSEC source: 0001209191-21-013382 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,810 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.71 to $87.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 14,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012413 · doc4.xml · derivative · entry 4 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,512 Underlying: Ordinary Shares · 14,512 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F3 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F3 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F3 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 3,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012413 · doc4.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,931 Underlying: Ordinary Shares · 3,931 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 871 | $87.17 | $75,925.07 |
DisclosureSEC source: 0001209191-21-012413 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,523 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 17:00 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 1,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012413 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,394 F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document |
| January 22, 2021 Filed Jan 22, 2021 21:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 2,731 | $76.81 | $209,768.11 |
DisclosureSEC source: 0001209191-21-004998 · doc4.xml · nonDerivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,429 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 20, 2020. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionPerformance Restricted Stock Units (PSUs) · Derivative | 4,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004998 · doc4.xml · derivative · entry 4 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,905 Underlying: Ordinary Shares · 4,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F3 · derivative.expiration_date: The shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,173 | $77.43 | $168,255.39 |
DisclosureSEC source: 0001209191-21-004998 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,160 Read SEC document |
| January 21, 2021 Filed Jan 22, 2021 21:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 4,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004998 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 17:31 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 30,031 | $75.00 | $2,252,325.00 |
DisclosureSEC source: 0001209191-21-002786 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,429 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 14, 2020. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 12,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002414 · doc4.xml · derivative · entry 7 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,190 Underlying: Ordinary Shares · 12,094 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002414 · doc4.xml · derivative · entry 6 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F5 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002414 · doc4.xml · derivative · entry 5 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,983 Underlying: Ordinary Shares · 17,983 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 49,906 | $73.28 | $3,657,111.68 |
DisclosureSEC source: 0001209191-21-002414 · doc4.xml · nonDerivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,460 Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 65,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002414 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,366 F2 · kind: On January 5, 2018 and January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2021, the PSUs vested as to the number of shares reported above. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 21:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 47,337 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-002414 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 20,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002414 · doc4.xml · derivative · entry 4 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,957 Underlying: Ordinary Shares · 20,957 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 13:24 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to buy) · Derivative | 11,172 | $0.00 Strike: $22.14 | $0.00 |
DisclosureSEC source: 0001209191-20-044992 · doc4.xml · derivative · entry 4 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,828 Underlying: Ordinary Shares · 11,172 shares Expires 2025-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 13:24 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionStock Option (Right to buy) · Derivative | 25,600 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001209191-20-044992 · doc4.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,600 shares Expires 2024-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 13:24 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 11,172 | $22.14 | $247,348.08 |
DisclosureSEC source: 0001209191-20-044992 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 13:24 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 25,600 | $9.23 | $236,288.00 |
DisclosureSEC source: 0001209191-20-044992 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP & President, International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 18:17 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 2,369 | $50.23 | $118,994.87 |
DisclosureSEC source: 0001209191-20-033715 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,169 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2020. F2 · balance_after: Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on June 1, 2020 pursuant to an employee stock purchase program. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 17:49 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 15,683 | $35.00 | $548,905.00 |
DisclosureSEC source: 0001209191-20-026399 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,489 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2020. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 17:49 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 30,063 | $35.01 | $1,052,505.63 |
DisclosureSEC source: 0001209191-20-026399 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,172 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.07 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 20:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 30,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011833 · doc4.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,014 Underlying: Ordinary Shares · 30,014 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. F1 · derivative.exercise_date: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. F1 · derivative.expiration_date: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 20:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 6,649 | $36.06 | $239,762.94 |
DisclosureSEC source: 0001209191-20-011833 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,235 Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 20:09 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 15,007 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011833 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,884 F1 · kind: On January 5, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 19, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2021 and January 5, 2022. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 16:18 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 10,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004656 · doc4.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,708 Underlying: Ordinary Shares · 10,708 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F1 · derivative.exercise_date: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F1 · derivative.expiration_date: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 16:18 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,372 | $38.25 | $90,729.00 |
DisclosureSEC source: 0001209191-20-004656 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,127 Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 16:18 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 5,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004656 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,499 F1 · kind: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document |
| January 21, 2020 Filed Feb 21, 2020 20:01 UTC Amendment | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantPerformance Restricted Stock Units (PSUs) · Derivative | 9,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011823 · doc4a.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,809 Underlying: Ordinary Shares · 9,809 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F1 · derivative.exercise_date: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F1 · derivative.expiration_date: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document |
| January 21, 2020 Filed Feb 21, 2020 20:01 UTC Amendment | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 2,173 | $38.25 | $83,117.25 |
DisclosureSEC source: 0001209191-20-011823 · doc4a.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,877 Read SEC document |
| January 21, 2020 Filed Feb 21, 2020 20:01 UTC Amendment | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 4,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011823 · doc4a.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,050 F1 · kind: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document |
| January 06, 2020 Filed Jan 7, 2020 18:23 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 9,297 | $35.62 | $331,159.14 |
DisclosureSEC source: 0001209191-20-002346 · doc4.xml · nonDerivative · entry 4 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,146 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2019. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.49 to $35.71 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:23 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002346 · doc4.xml · derivative · entry 7 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,260 Underlying: Ordinary Shares · 17,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F7 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F7 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:23 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002346 · doc4.xml · derivative · entry 6 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,966 Underlying: Ordinary Shares · 17,982 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F6 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F6 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:23 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 24,225 | $36.10 | $874,522.50 |
DisclosureSEC source: 0001209191-20-002346 · doc4.xml · nonDerivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,443 Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:23 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 19,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002346 · doc4.xml · nonDerivative · entry 2 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,668 F2 · kind: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2020, the PSUs vested as to the number of shares reported above. Read SEC document |
| January 05, 2020 Filed Jan 7, 2020 18:23 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 35,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-002346 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 18:23 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 36,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-002346 · doc4.xml · derivative · entry 5 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,284 Underlying: Ordinary Shares · 36,284 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F5 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 16:06 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 13,111 | $25.02 | $327,979.53 |
DisclosureSEC source: 0001209191-19-041045 · doc4.xml · nonDerivative · entry 1 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,412 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on June 5, 2019. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 2,369 ordinary shares of the Issuer acquired by the reporting person on May 31, 2019 pursuant to an employee stock purchase program. Read SEC document |
| March 23, 2019 Filed Mar 25, 2019 21:14 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021270 · doc4.xml · derivative · entry 3 Karnani Vikram · CIK 0001699488 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On March 23, 2015, the reporting person was granted 38,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On March 23, 2015, the reporting person was granted 38,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.